Myelofibrosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros

The Key Myelofibrosis Companies in the market include - Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others.

DelveInsight's "Myelofibrosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Myelofibrosis, historical and forecasted epidemiology as well as the Myelofibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Myelofibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myelofibrosis Market Forecast [https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Myelofibrosis Market Report:

*
The Myelofibrosis market size was valued USD 2,602 million in 2025 and is anticipated to reach USD 5,368 million by 2034 with a significant CAGR of 9.0% during the study period (2020-2034).

*
The Myelofibrosis market in the 7 major markets (7MM) was approximately USD 2.2 billion in 2024 and is expected to grow over the forecast period from 2024 to 2034.

*
In 2024, the U.S. represented the largest myelofibrosis market, valued at approximately USD 1,700 million, surpassing the EU4 (Germany, Italy, France, and Spain), the UK, and Japan.

*
In the 7 major markets (7MM), JAKAFI/JAKAVI (ruxolitinib) held the largest share of the myelofibrosis market in 2024, valued at around USD 1,500 million.

*
Demand for JAKAFI remains robust, with future growth anticipated as it continues to uphold its position as the standard of care for myelofibrosis.

*
The total prevalence of myelofibrosis in the 7 major markets (7MM) was approximately 55,900 in 2024 and is expected to rise over the study period from 2020 to 2034.

*
Within the EU4 and the UK, Germany had the highest number of diagnosed myelofibrosis cases in 2024, followed by Spain, while the UK reported the lowest case count.

*
Myelofibrosis cases are categorized by risk levels: low, intermediate-1, intermediate-2, and high. In 2024, high-risk patients represented the largest group in the U.S.

*
In the U.S., myelofibrosis cases are divided by age groups: less than or equal to 49 years, 50-69 years, and greater than or equal to 70 years. In 2024, the greater than or equal to 70 years age group had the highest number of patients, totaling approximately 12,100.

*
Key Myelofibrosis Companies: Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others

*
Key Myelofibrosis Therapies: LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, Momelotinib, and others

*
The Myelofibrosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myelofibrosis pipeline products will significantly revolutionize the Myelofibrosis market dynamics.

Myelofibrosis Overview

Myelofibrosis is a rare type of bone marrow disorder characterized by the abnormal production of blood cells, leading to scarring (fibrosis) in the bone marrow. In this condition, the bone marrow becomes increasingly fibrous, impairing its ability to produce normal blood cells. This can result in a decrease in the production of red blood cells, white blood cells, and platelets.

Get a Free sample for the Myelofibrosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/myelofibrosis-mf-market [https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Recent Developments In The Myelofibrosis Treatment Landscape:

*
In September 2025, Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company specializing in innovative cancer treatments, announced that it has finished enrolling patients in the Phase 3 SENTRY trial. The study is assessing selinexor combined with ruxolitinib in JAK inhibitor-naive patients with myelofibrosis.

*
In November 2024, MorphoSys announced favorable topline results from the Phase III MANIFEST-2 clinical trial evaluating pelabresib for myelofibrosis. The trial assessed pelabresib in combination with Jakafi (ruxolitinib) from Novartis and Incyte, compared to a placebo plus Jakafi, in JAK inhibitor-naive patients with myelofibrosis.

*
In October 2024, Ajax Therapeutics, Inc., a biopharmaceutical company focused on developing next-generation JAK inhibitors for myeloproliferative neoplasms (MPNs), has announced that the first patient has been dosed in its Phase 1 clinical trial of AJ111095, a novel Type II JAK2 inhibitor, for the treatment of myelofibrosis.

Myelofibrosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Myelofibrosis Epidemiology Segmentation:

The Myelofibrosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Myelofibrosis

*
Prevalent Cases of Myelofibrosis by severity

*
Gender-specific Prevalence of Myelofibrosis

*
Diagnosed Cases of Episodic and Chronic Myelofibrosis

Download the report to understand which factors are driving Myelofibrosis epidemiology trends @ Myelofibrosis Epidemiology Forecast [https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myelofibrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myelofibrosis market or expected to get launched during the study period. The analysis covers Myelofibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Myelofibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Myelofibrosis Therapies and Key Companies

*
JAKAFI/JAKAVI (ruxolitinib): Incyte/Novartis

*
INREBIC (fedratinib): Bristol Myers Squibb

*
XPOVIO (selinexor): Karyopharm Therapeutics

*
RYTELO (imetelstat): Geron Corporation

*
REBLOZYL (luspatercept/ACE-536): Bristol Myers Squibb

*
Navtemadlin (KRT-232): Kartos Therapeutics

*
Pelabresib (DAK539): Novartis

*
Bomedemstat (IMG-7289/MK-3543): Merck

*
TL-895: Telios Pharma

*
RVU120 ( SEL-120): Ryvu Therapeutics

*
TP-3654 (nuvisertib): Syntara

*
DISC-0974: Disc Medicine

*
ELZONRIS (tagraxofusp/SL-401): Menarini Group

Discover more about therapies set to grab major Myelofibrosis market share @ Myelofibrosis Treatment Landscape [https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myelofibrosis Market Drivers

*
Increase in R&D for the development of new and effective drug for the treatment - Increasing Incidence in Elderly Population, development of biological therapies or immunotherapies are some of the important factors that are fueling the Myelofibrosis Market.

Myelofibrosis Market Barriers

*
However, side effects associated with the drugs, high cost of therapy and other factors are creating obstacles in the Myelofibrosis Market growth.

Scope of the Myelofibrosis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Myelofibrosis Companies: Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others

*
Key Myelofibrosis Therapies: LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, Momelotinib, and others

*
Myelofibrosis Therapeutic Assessment: Myelofibrosis current marketed and Myelofibrosis emerging therapies

*
Myelofibrosis Market Dynamics: Myelofibrosis market drivers and Myelofibrosis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Myelofibrosis Unmet Needs, KOL's views, Analyst's views, Myelofibrosis Market Access and Reimbursement

To know more about Myelofibrosis companies working in the treatment market, visit @ Myelofibrosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Myelofibrosis Market Report Introduction

2. Executive Summary for Myelofibrosis

3. SWOT analysis of Myelofibrosis

4. Myelofibrosis Patient Share (%) Overview at a Glance

5. Myelofibrosis Market Overview at a Glance

6. Myelofibrosis Disease Background and Overview

7. Myelofibrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Myelofibrosis

9. Myelofibrosis Current Treatment and Medical Practices

10. Myelofibrosis Unmet Needs

11. Myelofibrosis Emerging Therapies

12. Myelofibrosis Market Outlook

13. Country-Wise Myelofibrosis Market Analysis (2020-2034)

14. Myelofibrosis Market Access and Reimbursement of Therapies

15. Myelofibrosis Market Drivers

16. Myelofibrosis Market Barriers

17. Myelofibrosis Appendix

18. Myelofibrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myelofibrosis-market-insights-highlight-expanding-outlook-till-2034-delveinsight-evaluates-lynk-pharma-samus-therapeutics-taiga-biotech-bristolmyers-squibb-sumitomo-pharma-oncology-keros]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.